Taysha Gene Therapies Announces Fast Track Designation Granted by US FDA for TSHA102 in Rett Syndrome Fast Track Designation FTD is designed to accelerate the development and expedite the review of therapies with potential to address unmet medical needs for a serious or lifethreatening condition TSHA102 has also received Orphan Drug and Rare Pediatric Disease designations from the United States US Food and Drug Administration FDA and has been granted Orphan Drug designation from the European Commission DALLAS Aug 24 2023 GLOBE NEWSWIRE  Taysha Gene Therapies Inc Nasdaq TSHA a clinicalstage gene therapy company focused on developing and commercializing AAVbased gene therapies for the treatment of monogenic diseases of the central nervous system CNS today announced the US FDA has granted Fast Track Designation FTD to TSHA102 a selfcomplementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome